Rivian Automotive, Inc. / DE RIVN
1 trading plan running, 29 Form 144 notices for $10.7M
10-Q, 10-K and Form 144What RIVN's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Jun 14, 2023 to Jun 12, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Michael Callahan Company’s Chief Administrative Officer and Chief Legal Officer |
Adopted 10b5-1 plan | Jun 12, 2026 | 10-Q Jul 30, 2026 | ||
What the company wroteOn June 12, 2026, Michael Callahan, the Company’s Chief Administrative Officer and Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 550,000 shares of the Company’s Class A common stock. Mr. Callahan’s Rule 10b5-1 trading arrangement is scheduled to expire no later than June 12, 2027. | |||||
| Robert J. Scaringe Company’s Founder and Chief Executive Officer |
Ended 10b5-1 plan | Jun 1, 2026 | 10-Q Jul 30, 2026 | ||
What the company wroteOn June 1, 2026, Robert J. Scaringe, the Company’s Founder and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement previously adopted on March 14, 2025 and amended on June 11, 2025. On June 12, 2026, Dr. Scaringe adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 1,142,025 shares of the Company’s Class A common stock. Dr. Scaringe’s Rule 10b5-1 trading arrangement is scheduled to expire no later than September 15, 2027. | |||||
| Karen Boone board of directors and Lead Independent Director |
Adopted 10b5-1 plan | Nov 24, 2025 | 10-K Feb 12, 2026 | ||
What the company wroteOn November 24, 2025, Karen Boone, a member of the Company’s board of directors and Lead Independent Director, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 20,000 shares of the Company’s Class A Common Stock. Ms. Boone’s Rule 10b5-1 trading arrangement is scheduled to expire no later than July 31, 2026. | |||||
| Claire McDonough Chief Financial Officer |
Adopted 10b5-1 plan | Sep 2, 2025 | 10-Q Nov 4, 2025 | ||
What the company wroteOn September 2, 2025, Claire McDonough, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 237,712 shares of the Company’s Class A Common Stock. Ms. McDonough’s Rule 10b5-1 trading arrangement is scheduled to expire no later than August 25, 2026. | |||||
| Robert J. Scaringe ’s Founder and Chief Executive Officer |
Adopted 10b5-1 plan | Mar 14, 2025 | 10-Q Aug 5, 2025 | ||
What the company wroteOn June 11, 2025, Robert J. Scaringe, the Company’s Founder and Chief Executive Officer, amended his Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, which he previously adopted on March 14, 2025, as disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the SEC on May 6, 2025. As amended, the Rule 10b5-1 trading arrangement covers the sale of up to 894,195 shares of the Company’s Class A common stock and is scheduled to expire no later than September 10, 2026. | |||||
| Robert J. Scaringe Company’s Founder and Chief Executive Officer |
Adopted 10b5-1 plan | Mar 14, 2025 | 10-Q May 6, 2025 | ||
What the company wroteOn March 14, 2025, Robert J. Scaringe, the Company’s Founder and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 3,500,000 shares of the Company’s Class A common stock. Dr. Scaringe’s Rule 10b5-1 trading arrangement is scheduled to expire no later than June 12, 2026. | |||||
| Claire McDonough Chief Financial Officer |
Adopted 10b5-1 plan | Aug 16, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteOn August 16, 2024, Claire McDonough, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 348,813 shares of the Company’s Class A common stock. Ms. McDonough’s Rule 10b5-1 trading arrangement is scheduled to expire no later than August 29, 2025. | |||||
| Robert J. Scaringe Founder and Chief Executive Officer |
Adopted 10b5-1 plan | Mar 8, 2024 | 10-Q May 7, 2024 | ||
What the company wroteOn March 8, 2024, Robert J. Scaringe, the Company’s Founder and Chief Executive Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 4,000,000 shares of the Company’s Class A common stock. Dr. Scaringe’s Rule 10b5-1 trading arrangement is scheduled to expire no later than June 9, 2025. | |||||
| Claire McDonough Chief Financial Officer |
Adopted 10b5-1 plan | Jun 14, 2023 | 10-Q Aug 8, 2023 | ||
What the company wroteOn June 14, 2023, Claire McDonough, the Company’s Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, for the sale of up to 279,936 shares of the Company’s Class A common stock. Ms. McDonough’s Rule 10b5-1 trading arrangement is scheduled to expire no later than August 20, 2024. | |||||
Show the other 1 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Oct 1, 2026 | MICHAEL J CALLAHAN Officer |
15,000 | $225K |
| Sep 11, 2026 | MICHAEL J CALLAHAN Officer |
15,000 | $244K |
| Aug 20, 2026 | CLAIRE R MCDONOUGH Officer |
8,023 | $128K |
| Aug 18, 2026 | CLAIRE R MCDONOUGH Officer |
13,144 | $191K |
| Jul 6, 2026 | RIVIAN FOUNDATION Affiliate |
166,668 | $3.1M |
| Jul 6, 2026 | KAREN BOONE Director |
20,000 | $373K |
| Jun 3, 2026 | CLAIRE R MCDONOUGH Officer |
8,022 | $144K |
| May 29, 2026 | CLAIRE R MCDONOUGH Officer |
8,023 | $128K |
| May 28, 2026 | ROBERT J. SCARINGE Officer, Director |
34,818 | $522K |
| May 21, 2026 | CLAIRE R MCDONOUGH Officer |
7,600 | $106K |
| May 18, 2026 | CLAIRE R MCDONOUGH Officer |
5,544 | $74K |
| Apr 22, 2026 | CLAIRE R MCDONOUGH Officer |
10,245 | $184K |
| Apr 14, 2026 | ROBERT J. SCARINGE Officer, Director |
21,446 | $347K |
| Mar 31, 2026 | ROBERT J. SCARINGE Officer, Director |
20,264 | $304K |
| Mar 17, 2026 | ROBERT J. SCARINGE Officer, Director |
17,450 | $272K |
| Mar 3, 2026 | ROBERT J. SCARINGE Officer, Director |
17,450 | $262K |
| Feb 25, 2026 | Rose Marcario Director |
7,183 | $111K |
| Feb 18, 2026 | ROBERT J. SCARINGE Officer, Director |
34,900 | $586K |
| Feb 18, 2026 | CLAIRE R MCDONOUGH Officer |
27,133 | $456K |
| Jan 20, 2026 | ROBERT J. SCARINGE Officer, Director |
17,450 | $280K |
| Jan 6, 2026 | RJ SCARINGE Officer, Director |
17,450 | $341K |
| Jan 2, 2026 | RIVIAN FOUNDATION Affiliate |
33,334 | $657K |
| Dec 23, 2025 | ROBERT J. SCARINGE Officer, Director |
17,450 | $374K |
| Dec 18, 2025 | Krawiec Peter Director |
3,655 | $71K |
| Dec 15, 2025 | Krawiec Peter Director |
5,572 | $108K |
| Dec 9, 2025 | RJ SCARINGE Officer, Director |
17,450 | $306K |
| Dec 4, 2025 | CLAIRE R MCDONOUGH Officer |
8,039 | $145K |
| Dec 2, 2025 | CLAIRE R MCDONOUGH Officer |
21,210 | $363K |
| Nov 25, 2025 | RJ SCARINGE Officer, Director |
17,450 | $264K |
Show the other 21 notices
From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RIVN/export.csv") into a cell.